6 Works

Data from: Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1/2 studies

Basil T. Darras, Claudia A. Chiriboga, Susan T. Iannaccone, Kathryn J. Swoboda, Jacqueline Montes, Laurence Mignon, Shuting Xia, C. Frank Bennett, Kathie M. Bishop, Jeremy M. Shefner, Allison M. Green, Peng Sun, Ishir Bhan, Sarah Gheuens, Eugene Schneider, Wildon Farwell & Darryl C. De Vivo
Objective: Report results of intrathecal nusinersen in children with later-onset spinal muscular atrophy (SMA). Methods: Analyses included children from the phase 1b/2a study (ISIS-396443-CS2; NCT01703988) who first received nusinersen during that study and were eligible to continue treatment in the extension study (ISIS-396443-CS12; NCT02052791). The phase 1b/2a study was a 253-day, ascending dose (3, 6, 9, 12 mg), multiple-dose, open-label, multicenter study that enrolled children with SMA aged 2 to 15 years. The extension study...

Data from: Comparing radiomic classifiers and classifier ensembles for detection of peripheral zone prostate tumors on T2-weighted MRI: a multi-site study

Satish E. Viswanath, Prathyush V. Chirra, Michael C. Yim, Neil M. Rofsky, Andrei S. Purysko, Mark A. Rosen, Nicolas B. Bloch & Anant Madabhushi
Background: For most computer-aided diagnosis (CAD) problems involving prostate cancer detection via medical imaging data, the choice of classifier has been largely ad hoc, or been motivated by classifier comparison studies that have involved larger synthetic datasets. More significantly, it is currently unknown how classifier choices and trends generalize across multiple institutions, due to heterogeneous acquisition and intensity characteristics (especially when considering MR imaging data). In this work, we empirically evaluate and compare a number...

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants

Heather M. Rozjabek, Craig I. Coleman, Veronica Ashton, François Laliberté, Paul Oyefesobi, Dominique Lejeune, Guillaume Germain, Jeff R. Schein, Zhong Yuan, Patrick Lefebvre & Eric D. Peterson
Objective: To assess long-term healthcare costs related to ischemic stroke and systemic embolism (stroke/SE) and major bleeding (MB) events in patients with non-valvular atrial fibrillation (NVAF) treated with non-vitamin K antagonist oral anticoagulants (NOACs). Materials and methods: Optum’s Clinformatics Data Mart database from 1/2009–12/2016 was analyzed. Adult patients with ≥1 stroke/SE hospitalization (index date) were matched 1:1 to patients without stroke/SE (random index date), based on propensity scores. Patients with an MB event were matched...

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants

Heather M. Rozjabek, Craig I. Coleman, Veronica Ashton, François Laliberté, Paul Oyefesobi, Dominique Lejeune, Guillaume Germain, Jeff R. Schein, Zhong Yuan, Patrick Lefebvre & Eric D. Peterson
Objective: To assess long-term healthcare costs related to ischemic stroke and systemic embolism (stroke/SE) and major bleeding (MB) events in patients with non-valvular atrial fibrillation (NVAF) treated with non-vitamin K antagonist oral anticoagulants (NOACs). Materials and methods: Optum’s Clinformatics Data Mart database from 1/2009–12/2016 was analyzed. Adult patients with ≥1 stroke/SE hospitalization (index date) were matched 1:1 to patients without stroke/SE (random index date), based on propensity scores. Patients with an MB event were matched...

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants

Heather M. Rozjabek, Craig I. Coleman, Veronica Ashton, François Laliberté, Paul Oyefesobi, Dominique Lejeune, Guillaume Germain, Jeff R. Schein, Zhong Yuan, Patrick Lefebvre & Eric D. Peterson
Objective: To assess long-term healthcare costs related to ischemic stroke and systemic embolism (stroke/SE) and major bleeding (MB) events in patients with non-valvular atrial fibrillation (NVAF) treated with non-vitamin K antagonist oral anticoagulants (NOACs). Materials and methods: Optum’s Clinformatics Data Mart database from 1/2009–12/2016 was analyzed. Adult patients with ≥1 stroke/SE hospitalization (index date) were matched 1:1 to patients without stroke/SE (random index date), based on propensity scores. Patients with an MB event were matched...

Data from: Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors

Bhaskar Roy, Avash Das, Kumar Ashish, Dhrubajyoti Bandyopadhyay, Abhishek Maiti, Sandipan Chakraborty, Martha E. Stone, Lisa Liang Philpotts, Richard J. Nowak & Huned S. Patwa
Objective: To explore the association of peripheral neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) use in cancer patients. Methods: Published data search up to November 2018 reporting peripheral neuropathy in cancer patients treated with VEGFR-TKIs was performed. The primary outcome was presence of peripheral neuropathy at the end of the trial. Random-effects meta-analysis was performed to estimate Relative Risk (RR) of individual treatment. Results: Thirty Randomized Clinical Trials (RCTs) including 12,490...

Registration Year

  • 2019
    6

Resource Types

  • Dataset
    6

Affiliations

  • The University of Texas Southwestern Medical Center
    6
  • Duke University
    3
  • Massachusetts General Hospital
    2
  • University of Pennsylvania
    1
  • Boston Children's Hospital
    1
  • Columbia University
    1
  • Ionis Pharmaceuticals (United States)
    1
  • Barrow Neurological Institute
    1
  • Biogen (United States)
    1
  • Interfaith Medical Center
    1